Acquired Hypothyroidism as a Predictive Marker of Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors: A Literature-Based Meta-Analysis

Clinical Genitourinary Cancer

Volumn 13, Issue 4, 2015, Pages 280-286

  Nearchou, Andreas ^a,b   Valachis, Antonis ^b   Lind, Pehr ^a,b   Akre, Olof ^a   Sandström, Per ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

mRCC; sorafenib; sunitinib; thyroid function; TKI

Indexed keywords

AXITINIB; PAZOPANIB; SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

HUMAN; HYPOTHYROIDISM; KIDNEY METASTASIS; MEDLINE; META ANALYSIS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; SYSTEMATIC REVIEW; CARCINOMA, RENAL CELL; CHEMICALLY INDUCED; KAPLAN MEIER METHOD; KIDNEY NEOPLASMS; MORTALITY; PATHOLOGY; SECONDARY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; HYPOTHYROIDISM; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME;

EID: 84936943166     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2014.10.002     Document Type: Review

References (39)

1. R.J. Motzer, T.E. Hutson, and P. Tomczak Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
2. J.S. Lam, J.T. Leppert, A.S. Belldegrun, and R.A. Figlin Novel approaches in the therapy of metastatic renal cell carcinoma World J Urol 23 2005 202 212
3. E.A. Singer, G.N. Gupta, and R. Srinivasan Targeted therapeutic strategies for the management of renal cell carcinoma Curr Opin Oncol 24 2012 284 290
4. E.M. Posadas, and R.A. Figlin Systemic therapy in renal cell carcinoma: advancing paradigms Oncology (Williston Park) 26 2012 290 301
5. M.H. Voss, A.M. Molina, and R.J. Motzer mTOR inhibitors in advanced renal cell carcinoma Hematol Oncol Clin North Am 25 2011 835 852
6. B. Escudier, and L. Albiges Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma Drugs 71 2011 1179 1191
7. A.M. Molina, and R.J. Motzer Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow Oncologist 16 suppl 2 2011 45 50
8. T.E. Hutson Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence Oncologist 16 suppl 2 2011 14 22
9. T. Powles, and T.E. Hutson Difficulty in predicting survival in metastatic renal cancer Lancet Oncol 13 2012 859 860
10. L.C. Harshman, W. Xie, and G.A. Bjarnason Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study Lancet Oncol 13 2012 927 935
11. J. Manola, P. Royston, and P. Elson Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group Clin Cancer Res 17 2011 5443 5450
12. M.E. Gore, and J.M. Larkin Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies Br J Cancer 104 2011 399 406
13. A. Ravaud Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies Oncologist 16 suppl 2 2011 32 44
14. J. Bellmunt, T. Eisen, C. Szczylik, P. Mulders, and C. Porta A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options BJU Int 107 2011 1190 1199
15. J.J. Patard, C. Porta, J. Wagstaff, and J.E. Gschwend Optimizing treatment for metastatic renal cell carcinoma Expert Rev Anticancer Ther 11 2011 1901 1911
16. H. Haddad, and B.I. Rini Current treatment considerations in metastatic renal cell carcinoma Curr Treat Options Oncol 13 2012 212 229
17. F. Zustovich, G. Lombardi, and P. Farina Treating patients with metastatic renal carcinoma: an escape from phase III Expert Rev Anticancer Ther 12 2012 919 927
18. T. Eisen, C.N. Sternberg, and C. Robert Targeted therapies for renal cell carcinoma: review of adverse event management strategies J Natl Cancer Inst 104 2012 93 113
19. K.J. Gotink, and H.M. Verheul Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 13 2010 1 14
20. N. Makita, and T. Iiri Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis Thyroid 23 2013 151 159
21. A. Ravaud, and M. Schmidinger Clinical biomarkers of response in advanced renal cell carcinoma Ann Oncol 24 2013 2935 2942
22. N. Shinohara, M. Takahashi, and T. Kamishima The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma Br J Cancer 104 2011 241 247
23. J.F. Tierney, L.A. Stewart, D. Ghersi, S. Burdett, and M.R. Sydes Practical methods for incorporating summary time-to-event data into meta-analysis Trials 8 2007 16
24. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Controlled Clinical Trials 7 1986 177 188
25. A. Sella, A.H. Hercbergs, E. Hanovich, and S. Kovel Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinoma? Chemotherapy 58 2012 200 205
26. A. Pinto, V. Moreno, E. Espinosa, A. Redondo, and M. Gonzalez Baron New onset hypothyroidism and macrocytosis as surrogate markers for the efficacy of sunitinib in the treatment of advanced renal cell carcinoma Genitourinary Cancers Symposium 2010 abstract 338
27. F.A.I. Pinto, A.A.R. Pereira, M.N. Formiga, M.F. Fanelli, L.T.D. Chinen, and V.C. Lima Association of hypothyroidism with improved outcomes in first-line treatment of renal cell carcinoma with sunitinib J Clin Oncol 30 2012 abstract 466
28. K.T. Papazisis, L. Kontovinis, K. Pazaitou, M. Kontovini, D. Mouratidou, and T. Vassileiadis Thyroid-stimulating hormone (TSH) levels in patients with metastatic renal cell cancer treated with sunitinib Ann Oncol 21 2010 289
29. V. Baldazzi, R. Tassi, A. Lapini, C. Santomaggio, M. Carini, and R. Mazzanti The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study Urol Oncol 30 2012 704 710
30. J. Clemons, D. Gao, M. Naam, K. Breaker, D. Garfield, and T.W. Flaig Thyroid dysfunction in patients treated with sunitinib or sorafenib Clin Genitourin Cancer 10 2012 225 231
31. L.M. Riesenbeck, S. Bierer, and I. Hoffmeister Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib World J Urol 29 2011 807 813
32. R. Sabatier, J.C. Eymard, and J. Walz Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma? Ann Oncol 23 2012 714 721
33. M. Schmidinger, U.M. Vogl, and M. Bojic Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer 117 2011 534 544
34. P. Wolter, C. Steffan, B. Decallonne, H. Dumez, S. Fieuws, and H. Wildiers Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC) J Clin Oncol 26 2008 abstract 5126
35. J. Ozao-Choy, G. Ma, and J. Kao The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenviroment for immune-based cancer therapies Cancer Res 69 2009 2514 2522
36. G. Mazziotti, F. Sorvillo, and C. Naclerio Type-1 response in peripheral CD4+ and CD8+ T cells from patients with Hashimoto's thyroiditis Eur J Endocrinol 148 2003 383 388
37. M. Grossmann, E. Premaratne, J. Desai, and I.D. Davis Thyrotoxicosis during sunitinib treatment for renal cell carcinoma Clin Endocrinol (Oxf) 69 2008 669 672
38. F.S. Hodi, S.J. O'Day, and D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
39. E. Wong, L.S. Rosen, and M. Mulay Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity Thyroid 17 2007 351 355